Home / Research library / Thymosin Alpha-1
Compound guide
Thymosin Alpha-1: what the research covers
A twenty-eight residue thymic peptide with an acetylated amino terminus, and the only compound in this catalogue that is an approved medicine in a substantial number of countries.
What Thymosin Alpha-1 is
The thymus produces a family of peptides collectively called thymosins, and thymosin alpha-1 is the best characterised of them: twenty-eight residues, cleaved from the precursor prothymosin alpha, with an acetyl group on the amino terminus. That acetylation is part of the molecule, not an artefact, and a preparation lacking it is a different compound.
Its reported activity is immunomodulatory rather than immunostimulatory, which is a distinction the literature takes seriously. Published mechanisms include signalling through Toll-like receptors on dendritic cells, influence on T-cell maturation and on the balance between helper subsets, and effects on natural killer cell activity. The framing in most of the work is restoration of a disordered response rather than amplification of a normal one.
It is used clinically as thymalfasin in a number of countries, principally in hepatitis and as an adjuvant in immunocompromised states, which gives it an evidence base of a kind almost nothing else in this catalogue has.
Why it sits in the longevity group
Thymic involution is one of the more reliably documented features of ageing: the thymus shrinks and its output of naive T cells falls, which is a plausible contributor to the immune decline that accompanies age. A thymic peptide is therefore of interest to ageing research for a structural reason rather than by analogy.
The companion compound here is Thymalin, a thymic extract rather than a single defined peptide, and the contrast between them is instructive: one is a characterised molecule with regulatory approval, the other a preparation whose composition is not fully specified. Work that needs attribution to a defined sequence needs the former.
Research strands cover T-cell reconstitution, vaccine response in older animals, sepsis and inflammatory models, and the mechanism of Toll-like receptor engagement, which remains incompletely resolved.
How Amino Club supplies it
Supplied lyophilised in sealed vials as Thymosin Alpha-1, specified at 99% purity or better by HPLC with identity confirmed by mass spectrometry and released against the batch Certificate of Analysis. The lab testing page documents the release sequence.
The amino-terminal acetyl group adds forty-two to the mass, which makes the mass spectrum the direct check on whether the vial contains the acetylated peptide or the unmodified sequence — a difference that matters because the activity is reported to depend on it. The powder is held below −18 °C and solutions prepared in small volumes, kept cold. Diluents are under reconstitution supplies.
Related reading
Thymosin Alpha-1 sits in the longevity research peptides group with Thymalin, Epithalon, NAD+, MOTS-c, SS-31 and FOXO4-DRI.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
Thymosin Alpha-1 supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.